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Tennessee; New York and Buffalo, New York; St. Louis, Missouri; and Lexington, KentuckyObjectives The aim of this study was to determine the relative utility of anatomic and ischemic
burden of coronary artery disease for predicting outcomes.
Background Both anatomic burden and ischemic burden of coronary artery disease determine
patient prognosis and inﬂuence myocardial revascularization decisions. When both measures are
available, their relative utility for prognostication and management choice is controversial.
Methods A total of 621 patients enrolled in the COURAGE (Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation) trial with baseline quantitative nuclear single-
photon emission computed tomography (SPECT) and quantitative coronary angiography were studied.
Several multiple regression models were constructed to determine independent predictors of the
endpoint of death, myocardial infarction (MI) (excluding periprocedural MI) and non–ST-segment
elevation acute coronary syndromes (NSTE-ACS). Ischemic burden during stress SPECT, anatomic
burden derived from angiography, left ventricular ejection fraction, and assignment to either optimal
medical therapy (OMT) þ percutaneous coronary intervention (PCI) or OMT alone were analyzed.
Results In nonadjusted and adjusted regression models, anatomic burden and left ventricular
ejection fraction were consistent predictors of death, MI, and NSTE-ACS, whereas ischemic burden and
treatment assignment were not. There was a marginal (p ¼ 0.03) effect of the interaction term of
anatomic and ischemic burden for the prediction of clinical outcome, but separately or in combination,
neither anatomy nor ischemia interacted with therapeutic strategy to predict outcome.
Conclusions In a cohort of patients treated with OMT, anatomic burden was a consistent predictor of
death, MI, and NSTE-ACS, whereas ischemic burden was not. Importantly, neither determination, even
in combination, identiﬁed a patient proﬁle beneﬁting preferentially from an invasive therapeutic
strategy. (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE];
NCT00007657) (J Am Coll Cardiol Intv 2014;7:195–201) ª 2014 by the American College of
Cardiology Foundation
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196Measures of either anatomic or ischemic burden are rou- prognostic importance of quantitative assessment of angio-
tinely used clinically to assess prognosis and select treatment
strategies (1). The COURAGE (Clinical Outcomes Uti-
lizing Revascularization and Aggressive Drug Evaluation)
trial showed noninferiority between a strategy of initial
optimal medical therapy (OMT) þ percutaneous coronary
intervention (PCI) and OMT alone for prevention of death
or myocardial infarction (MI) (2). A substudy of 314 pa-
tients with baseline and follow-up nuclear studies showed
that OMT þ PCI was associated with a greater decrease in
ischemia as measured by quantitative stress single-photonSee page 202emission computed tomography (SPECT) and that the
presence of at least a moderate degree of baseline ischemia
might be a predictor of beneﬁt from an initial strategy
of OMT þ PCI (3). A subsequent analysis of all patientsFrom the *University of British Col
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OMT = optimal medical
therapy
PCI = percutaneous coronary
intervention
SPECT = single-photon
emission computedfor whom pre-randomization
SPECT information was avail-
able reported no decrease in
death or MI among patients with
moderate to severe ischemia who
were randomized to OMT þ
PCI (4). Although several quan-
titative angiographic analyses of
the COURAGE trial have dem-
onstrated the prognostic impor-
tance of baseline angiographic
characteristics and left ventricular
function status, none have clearly
identiﬁed an anatomic subset fa-
voring an initial OMT þ PCI
strategy (5–7) and no direct
comparison with ischemic burdenhas been conducted. The purpose of the current analysis was
2-fold: 1) to explore the relative and potentially synergistic
tomographyumbia, Vancouver, British Columbia, Canada;
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for the prediction of death, MI, or non–ST-segment elevation
acute coronary syndrome (NSTE-ACS) while on OMT; and
2) to determine whether a combination of anatomic and
ischemic burden would identify patients who would beneﬁt
from an initial PCI management strategy.
Methods
The main trial results, assessment methods for quantitative
nuclear ischemic burden, methods for quantitative coro-
nary angiography, and deﬁnitions of clinical endpoints
have been previously published (2). The clinical endpoint
for this analysis was a composite of death, MI, and NSTE-
ACS. Periprocedural MIs were excluded from all analyses.
SPECT and coronary angiography studies were analyzed
in core laboratories. SPECT myocardial perfusion studies
were analyzed quantitatively using the measurement of the
total perfusion defect, combining perfusion defect extent
and severity on a continuous pixel-by-pixel basis and ex-
pressed as a percent of the total left ventricular myocar-
dium (QPS, Cedars-Sinai Medical Center, Los Angeles,
California) (8). The percent of ischemic myocardium was
calculated by subtracting the rest from the stress total
perfusion defect and used as a continuous variable. Con-
trast coronary angiograms were assessed for the presence of
stenoses 50% in the major epicardial vessels and primary
branches (5). Patients who failed to meet the 50% diameter
stenosis threshold by quantitative coronary angiography
were designated as having “no” vessel disease. By dis-
tinguishing between proximal and nonproximal left ante-
rior descending and circumﬂex artery disease, different
gradations of single-, double-, and triple-vessel disease
could be described anatomically, thereby creating an
anatomic burden score suitable for use as a continuous
variable (0 to 17 scoring scale; see Table 1). By design ofaventis, First Horizon, and GE Healthcare, including in-kind support with U.S. Food
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Table 1. Grading Scale for Anatomic Burden of Disease on the Basis of











2 LCX (not proximal LCX) 1
3 Proximal LCX 1
4 LAD (not proximal LAD) 1
5 Proximal LAD 1
6 LCX (not proximal LCX) þ RCA 2
7 Proximal LCX þ RCA 2
8 LAD (not proximal LAD) þ RCA 2
9 Proximal LAD þ RCA 2
10 LAD (not proximal LAD) þ LCX
(not proximal LCX)
2
11 Proximal LAD þ LCX (not proximal LCX) 2
12 LAD (not proximal LAD) þ proximal LCX 2
13 Proximal LAD þ proximal LCX 2
14 LAD (not proximal LAD) þ LCX
(not proximal LCX) þ RCA
3
15 LAD (not proximal LAD) þ proximal LCX þ RCA 3
16 Proximal LAD þ LCX (not proximal LCX) þ RCA 3
17 Proximal LAD þ proximal LCX þ RCA 3
LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex artery; RCA ¼ right coronary artery.
Table 2. Characteristics of Patients With Both Quantitative Nuclear and








Female 36 (12) 42 (14) 0.42
White 244 (78) 251 (81) 0.31
Hypertension 233 (75) 227 (74) 0.73
Diabetes 115 (37) 121 (40) 0.55
Family history of Coronary
Artery Disease
155 (56) 145 (54) 0.63
Current smoker 85 (27) 80 (26) 0.74
Heart failure 20 (6) 11 (4) 0.11
Previous MI 116 (38) 110 (36) 0.78
Previous PCI 54 (17) 47 (15) 0.51
Previous CABG 52 (17) 37 (12) 0.11
CCS
0 39 (12) 38 (37) 0.98
I 118 (38) 114 (37)
II 96 (31) 99 (32)
III 60 (19) 57 (19)
Age, yrs 62.1  10.3 62.6  10.1 0.56
BMI, kg/m2 29.5  4.9 30.1  5.5 0.71
Perfusion defect, % 7.7  5.7 7.8  6.2 0.79
LVEF, % 60.1  11.8 60.7  10.0 0.46
Anatomic burden score (0–17) 7.8  4.9 7.4  4.8 0.24
Angina frequency, episodes/week 3 (1–5) 2 (1–5) 0.68
Angina duration, yrs 3 (1–12) 3 (1–8) 0.33
LDL, mg/dl 99 (78–123) 100 (81–121) 0.76
HDL, mg/dl 37 (32–46) 39 (33–45) 0.09
Triglycerides, mg/dl 154 (103–217) 152 (102–213) 0.81
Values are mean (%), mean  SD, or median (interquartile range).
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; CCS ¼ Canadian Cardio-
vascular Society; HDL ¼ high-density lipoprotein; IQR ¼ interquartile range; LDL ¼ low-density
lipoprotein; LVEF ¼ left ventricular ejection fraction; MI ¼myocardial infarction; OMT ¼ optimal
medical therapy; PCI ¼ percutaneous coronary intervention.
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197the COURAGE trial, there were no patients with left
main coronary artery disease.
Multiple logistic survival analysis was used to determine
independent predictors of death, MI, and NSTE-ACS.
Left ventricular ejection fraction (LVEF) was included a
priori in all logistic regression analyses to account for the
effects of irreversible ventricular damage and irreversible
ischemia that would otherwise confound the interpreta-
tion of the nuclear and angiographic assessments. Other
factors that might affect generalizability were identiﬁed by
comparison of the patients in this analysis with the
remaining patients enrolled in the trial. Between-group
comparisons were undertaken using the t, chi-square, or
Fisher exact test where appropriate. Logistic regression
analyses were repeated to adjust for differences in this
cohort compared with the overall COURAGE trial
cohort. Results with p < 0.01 were considered statistically
signiﬁcant.
Results
There were 621 patients with quantitative angiographic and
nuclear data. The mean follow-up was 4.69  1.68 years.
There were 185 events (death/MI/NSTE-ACS) in the 621
patients, yielding a raw rate of events of 29.8% and an overall
event rate of 30.2%/4.69 years taking into account individual
follow-up time and censoring of recurrent events. Table 2shows the characteristics of this study group by randomi-
zation to OMT þ PCI or OMT; no differences were
detected. Table 3 shows a comparison of this group with the
remaining patients enrolled in the trial. The current study
cohort, compared with the overall COURAGE trial popu-
lation, had signiﬁcantly fewer white, more hypertensive,
more diabetic, more previous coronary artery bypass graft
(CABG) surgery, fewer patients with Canadian Cardiovas-
cular Society class II and III, and more triple-vessel disease
patients. Additionally, angina duration was shorter and
high-density lipoprotein levels were lower. These factors
were used to adjust results.
Table 4 shows the results of 3 different multiple logistic
regression analyses with model 1 containing only the pri-
mary factors of interest and models 2 and 3 including
interaction terms. Treatment assignment to OMT þ PCI or
OMT did not predict outcome in any model; similarly, nor
did ischemic burden (Fig. 1). Consistent predictors were
LVEF and anatomic burden of disease (Fig. 2). These
Table 3. Characteristics of Patients in the Current Study Compared With





(N ¼ 1,666) p Value
Female 78 (13) 260 (16) 0.07
White 495 (80) 1,468 (89) <0.001
Hypertension 460 (75) 1,061 (65) <0.001
Diabetes 236 (38) 530 (32) 0.008
Family history of Coronary
Artery Disease
300 (55) 793 (53) 0.43
Current smoker 165 (27) 488 (29) 0.19
Heart failure 31 (5) 77 (5) 0.70
Previous MI 226 (37) 650 (40) 0.24
Previous PCI 101 (16) 258 (16) 0.64
Previous CABG 89 (14) 159 (10) 0.001
CCS
0 77 (12) 206 (12) <0.001
I 232 (37) 449 (27)
II 195 (31) 639 (38)
III 117 (19) 365 (22)
Age, yrs 62.4  10.2 62.0  9.8 0.42
BMI, kg/m2 29.8  5.2 29.5  5.0 0.25
Angina frequency, episodes/week 3 (1–5) 3 (1–6) 0.43
Angina duration, yrs 3 (1–9) 6 (2–21) <0.001
LDL, mg/dl 99 (80–122) 101 (82–124) 0.27
HDL, mg/dl 38 (33–45) 40 (33–47) <0.001
Triglycerides, mg/dl 152 (102–214) 145 (104–210) 0.08
Values are mean (%), mean  SD, or median (interquartile range).
Abbreviations as in Table 2.
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198results were not materially changed after adjusting for the
confounders listed in the preceding text. Of the multiple
confounders, a history of hypertension and CABG surgeryTable 4. Multiple Logistic Survival Analyses to Determine Predictors of Death, M
Variables
Model 1 (No Interactions) Model 2 (Interactions W
OR
(95% CL) p Value Variables
Treatment assignment* 1.00 (0.75–1.34) 1.00 Treatment assignment 1.0
Ischemic burden 1.01 (0.98–1.03) 0.54 Ischemic burden 1.0
LVEFy 0.98 (0.97–1.00) 0.0095 LVEF 0.9











*Optimal medical therapy or optimal medical therapy þ percutaneous coronary intervention. yLVEF.
CL ¼ conﬁdence limits; NSTE-ACS ¼ non–ST-segment elevation acute coronary syndrome; OR ¼ odwere additional consistent and independent predictors of
death, MI, or NSTE-ACS (data not shown).
Model 2 (Table 4) shows the absence of any interaction
between treatment and LVEF, anatomic burden, ischemic
burden, or the combination of anatomic and ischemic
burden. The only interaction approaching statistical sig-
niﬁcance was between anatomic and ischemic burden
(p ¼ 0.03) (model 3 in Table 4). Figure 3 explores this
interaction further. The basis of the borderline positive
interaction term appears in Figure 3 to emerge predomi-
nantly from the progressively higher event rates within the
higher atherosclerotic burden group. The event rate was
progressively higher with increasing ischemic burden only
in patients with high atherosclerotic burden. In contrast,
event rates were generally progressively higher on the basis
of the degree of anatomic burden, irrespective of amount of
ischemic myocardium.
Discussion
Anatomic burden assessed by coronary angiography and
ischemic burden assessed by stress SPECT myocardial
perfusion imaging are commonly used to assess prognosis,
and both inﬂuence therapy in patients with stable ischemic
heart disease. Accordingly, this analysis was designed to
directly compare these 2 risk stratiﬁcation methods and to
explore whether they could also identify patients with greater
beneﬁts from an initial intervention strategy. Our analyses
indicate that when both anatomic burden and ischemic
burden of disease at baseline are considered concomitantly,
ischemic burden was not an independent predictor of death,
MI, or NSTE-ACS. In contrast, anatomic burden andI, or NSTE-ACS
ith Treatment) Model 3 (Interactions With Each Other)
OR
(95% CL) p Value Variables
OR
(95% CL) p Value
3 (0.76–1.39) 0.84 Treatment assignment 1.01 (0.76–1.36) 0.93
1 (0.99–1.03) 0.46 Ischemic burden 1.01 (0.98–1.04) 0.54
8 (0.97–1.00) 0.006 LVEF 0.98 (0.97–0.99) 0.003
5 (1.02–1.08) 0.003 Atherosclerotic burden 1.05 (1.02–1.09) <0.001
0.07 Interaction of ischemic
burden and LVEF
0.50




0.07 Interaction of LVEF and
atherosclerotic burden
0.19




ds ratio; other abbreviations as in Table 2.
Figure 1. Freedom From Death, MI, or NSTE-ACS by Percent of Ischemic
Myocardium
The number of patients pertaining to each colored curve are shown per year
of follow-up. The percent of ischemic myocardium is calculated as described
in the text and represents the burden of reversible ischemia at baseline. No
signiﬁcant relationship with the outcome of death/myocardial infarction (MI)/
non–ST-segment elevation acute coronary syndromes (NSTE-ACS) was
detected (p ¼ 0.75).
Figure 2. Freedom From Death, Myocardial Infarction, or Non–ST-Segment
Elevation Acute Coronary Syndrome by Anatomic Burden
The number of patients pertaining to each colored curve are shown per year
of follow-up. The atherosclerotic burden of disease was determined using the
graduated scale shown in Table 1. The clusters of 0-5, 6-13, and 14-17 corres-
pond to traditional vessel disease designations of 0/1, 2, and 3 vessel disease,
respectively. Angiographic burden of disease was signiﬁcantly predictive of
death/MI/NSTE-ACS (p ¼ 0.001). Abbreviations as in Figure 1.
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199LVEF were consistently seen to be independent predictors
of death, MI, or NSTE-ACS. The interaction term of
ischemic burden and anatomic burden at baseline was of
only borderline signiﬁcance as a predictor of death, MI, or
NSTE-ACS, where it was primarily of beneﬁt in risk-strat-
ifying the outcomes of those with the most severe anatomic
burden. More importantly, none of these factors identiﬁed
patients who would beneﬁt from an initial invasive strategy.
These results are concordant with a recent analysis of
nearly 1,400 patients in the COURAGE trial showing that
the extent of site-deﬁned ischemia did not predict adverse
events and did not alter treatment effectiveness (4). These
results are also concordant with a recent analysis of the
STICH (Comparison of Surgical and Medical Treatment
of Congestive Heart Failure and Coronary artery Disease)
trial in patients with severely reduced LVEF, which
concluded that inducible ischemia did not identify patients
with worse prognosis or those with greater beneﬁt from
revascularization with CABG surgery over OMT (9).
Similarly, a nuclear substudy of the BARI 2D (Bypass
Angioplasty Revascularization Investigation 2 Diabetes) trial
showed that LVEF, but not the percent of ischemic
myocardium, predicted event rates (10). Our results allow
extension of this concept to nondiabetic patients, LVEF
>35%, and revascularization with PCI.
Our data suggesting that ischemia may be most impor-
tant in those with more severe atherosclerotic burden(Fig. 3) provide an important justiﬁcation for the ongoing
ISCHEMIA (International Study of Comparative Health
Effectiveness with Medical and Invasive Approaches
(ISCHEMIA). The ISCHEMIA trial uses coronary
computed tomography to exclude patients with signiﬁcant
left main coronary artery or minimal atherosclerotic disease
and will randomize 8,000 patients with at least moderate
ischemia to an initial invasive strategy of catheterization
followed by revascularization (PCI or CABG) as
warranted þ OMT versus an initial conservative strategy of
OMT alone with catheterization and revascularization
reserved for patients in whom OMT failed. It will be
possible to determine whether ischemic burden at baseline
retains prognostic power while receiving OMT. The size of
this study will overcome any sample size limitations in the
current analysis and will deﬁne the incremental contribution
of ischemia to atherosclerotic burden for prognostication and
selection of an optimal management strategy.
Our current ﬁndings are discordant with observational
cohort studies implying that the severity of ischemic burden
can identify patients who would beneﬁt from an invasive
revascularization strategy (11–17). This may be explained
by the strict adherence to protocol-driven OMT in the
current cohort, which cannot be mandated in observational
studies. In addition, the difﬁculties of fully assessing and
adjusting for confounders in observational studies are well
known.
Figure 3. Proportion of Patients With Death, Myocardial Infarction or Non–ST-Segment Elevation Acute Coronary Syndrome by Ischemic Myocardium
and Atherosclerotic Burden of Disease
The borderline interaction between ischemic and angiographic burden of disease for prediction of outcome is explored further in this plot showing the relationship of
these parameters to the outcomes of death/MI/NSTE-ACS when considered concomitantly. Outcome worsens in a generally consistent fashion with increasing
atherosclerotic burden of disease. Outcome does not worsen consistently with increasing ischemic burden except in the subset of patients with the highest degree of
atherosclerotic burden. p ¼ 0.03 and not signiﬁcant for COURAGE post-hoc analyses. See Methods and Table 4, model 3. Abbreviations as in Figure 1.
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200There may, however, also be important physiological
reasons for the ﬁndings. It is apparent that OMT has the
ability to reduce ischemic burden, but not as rapidly or
extensively as PCI in the short term (3,18,19). OMT may
achieve a sizable reduction in ischemia and comparable
reduction in angina-free status over the long term (2).
Thus, the overlapping anti-ischemic nature of both stra-
tegies may contribute over the long term to the abrogation
of the prognostic importance of baseline, pre-treatment
inducible ischemia. The vasculoprotective effect of OMT,
with respect to plaque stabilization and progression, may
also partially explain the inability to identify an advantage
over the long term of OMT þ PCI versus OMT alone.
However, neither sufﬁciently reverses the burden of
atherosclerosis, and neither completely suppresses pro-
gression or plaque disruption throughout the entire coro-
nary tree (6). Because increasing burden of signiﬁcant
anatomic stenoses is likely to also be associated with more
subclinical atherosclerotic lesions (i.e., nonobstructing
plaques that may be “vulnerable”), adverse clinical out-
comes that occur may be greatly inﬂuenced by their
disruption more so than by the ﬂow-limiting nature of
obstructive plaques. Thus, baseline anatomic disease re-
tains value as an index or surrogate measure of the extent
of fertile soil for future cardiac events.
Study limitations. This analysis has limitations derived
from its post hoc nature, the relatively small sample size(n ¼ 621), the potential for residual confounding despite
the adjustments undertaken, the lack of serial assessments
of inducible ischemia after implementation of OMT with
or without PCI, the inability to retrospectively calculate
more detailed angiographic indexes such as SYNTAX
score, the absence of lesion-speciﬁc fractional ﬂow reserve
measurements, and execution during the bare metal stent
era. Despite these limitations, the ﬁndings are concordant
with the emerging concepts identiﬁed in other similar an-
alyses (4,9) and extend the implications to include a very
demographically broad group of patients (diabetic and
nondiabetic, normal or only mildly depressed LVEF,
revascularization with stents or CABG) in the context of
modern evidence-based medical therapy complemented by
either elective or urgent PCI. The ﬁndings further chal-
lenge the existing paradigm regarding the role of inducible
ischemia in choosing a revascularization strategy, thereby
also underscoring the critical need to re-evaluate this
concept through the ongoing ISCHEMIA trial.
Conclusions
In patients treated with OMT with or without elective or
symptom-warranted PCI, anatomic burden of coronary
disease, but not ischemic burden, predicted the risk of death,
MI, and NSTE-ACS, but neither coronary anatomy nor
ischemia, even in combination, identiﬁed a patient proﬁle
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201beneﬁting preferentially from an initial invasive therapeutic
strategy.
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